Elesclomol directly targets FDX1 in human breast cancer and lung adenocarcinoma cells, inhibits FDX1-mediated Fe-S cluster biosynthesis, and promotes copper-dependent cell death (Tsvetkov et al., 2019). The gene discussed is FDX1; the disease is breast cancer.